GlassScriptPhysician profile
Ashley O Mo
NPI 1417375049
$3,011.37
in general payments reported to CMS, 2019-2025
28 companies · $261 in 2025
The $261 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $191 · 2021: $552 · 2022: $740 · 2023: $505 · 2024: $382 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $339.67 | 2022-2023 | Opzelura |
| Glaxosmithkline, LLC. | $324.57 | 2020-2025 | Bexsero, Pediarix, Menveo |
| Abbvie INC. | $274.94 | 2019-2022 | |
| Novo Nordisk INC | $231.01 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $225.05 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $194.04 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $182.70 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $145.86 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $142.32 | 2024 | |
| Pfizer INC. | $120.18 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $119.22 | 2019 | |
| Abbott Laboratories | $112.32 | 2022 | |
| Biogen, INC. | $89.16 | 2021 | |
| Sanofi-Aventis U.S. LLC | $87.08 | 2025 | |
| Kaleo, INC. | $73.09 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $71.47 | 2019-2020 | |
| Seqirus USA INC | $52.86 | 2021-2022 | |
| Sanofi Pasteur INC. | $39.45 | 2021-2025 | |
| Phadia US INC. | $28.95 | 2021-2025 | Immunocap |
| Verrica Pharmaceuticals INC. | $22.80 | 2025 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $22.24 | 2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $20.02 | 2025 | Neffy |
| Cranial Technologies, INC | $19.86 | 2025 | Doc Band |
| Alexion Pharmaceuticals, INC. | $18.87 | 2024 | Koselugo |
| Vertical Pharmaceuticals, LLC | $16.92 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.63 | 2019 | |
| Shire North American Group INC | $12.99 | 2019 | |
| Corium, LLC | $9.10 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.